Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company’s stock to newly hired employees on October 8, 2024, in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer. The Inducement Grants were granted pursuant to Aligos’ 2024 Employment Inducement Award Plan as an inducement material to entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos. The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grants will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.